| Assessment Status | Rapid review complete |
| HTA ID | 21070 |
| Drug | Sotorasib |
| Brand | Lumykras® |
| Indication | As monotherapy for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 20/12/2021 |
| Rapid review completed | 25/01/2022 |
| Rapid review outcome | A full HTA is not recommended until additional efficacy and/or safety data is submitted. On the basis of current evidence, the NCPE recommends that sotorasib not be considered for reimbursement* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
